Teva to discontinue Phase 2 Topas-MSA study of emrusolmin following interim futility analysis
TEVA•Teva will discontinue its Phase 2 Topas-MSA study of emrusolmin (TEV-‘286) after an interim analysis indicated a low probability that the study would meet its primary efficacy endpoint if continued.
1. Study to stop
Teva said it will discontinue the Phase 2 Topas-MSA study of emrusolmin (TEV-‘286) following an interim futility analysis. The predictive analysis indicated a low probability that the study would meet its primary efficacy endpoint if continued.
